Bristol Myers Squibb (BMY) Asset Writedowns and Impairment (2010 - 2026)

Bristol Myers Squibb has disclosed Asset Writedowns and Impairment across 17 years of filings, most recently posting $412.0 million for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment rose 8140.0% year-over-year to $412.0 million; the TTM figure through Mar 2026 stood at $1.5 billion (down 49.28% YoY), while the FY2025 annual figure was $1.1 billion, down 62.94% from the prior year.
• Asset Writedowns and Impairment slipped to $412.0 million in Q1 2026, from $584.0 million in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for BMY reached as high as $2.0 billion in Q4 2024 and fell as low as $1.0 million in Q1 2024.
• The 5-year median for Asset Writedowns and Impairment is $61.0 million (2022), against an average of $288.6 million.
• Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment tumbled 95.0% — and 2026, when it soared 8140.0%.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $35.0 million in 2022, then slipped by 17.14% to $29.0 million in 2023, then soared by 6634.48% to $2.0 billion in 2024, then plunged by 70.1% to $584.0 million in 2025, then decreased by 29.45% to $412.0 million in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $412.0 million, $584.0 million, and $196.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.